Per the company, more than 11,800 patients are on Rezdiffra treatment as of year-end 2024. Preliminary report suggests that Madrigal’s year-end 2024 cash, cash equivalents, restricted cash and ...

expand Madrigal Pharmaceuticals' NASH pill Rezdiffra is FDA-approved treatment for the fatty liver disease. Madrigal Pharrmaceuticals "I will ask you to look at any [new drug] launch," said Sibold ...

Shares of Madrigal Pharmaceuticals MDGL lost 9.7% on Tuesday as the investors were not impressed by its preliminary ...

The company said that its preliminary results indicated it earned $100 million to $103 million in the fourth quarter from Rezdiffra, its treatment for metabolic dysfunction-associated ...

These initiatives have positioned Rezdiffra's early launch favorably in comparison to other top-tier specialty drugs and have secured a significant first-to-market advantage, which is crucial for ...

While medication can provide symptom relief, it does not necessarily address underlying maladaptive behaviors, and is therefore considered by many clinicians and adjunct to treatment, rather than ...

At the end of the year, the company added, over 11,800 patients were taking the medication ... I feel that they might be overly bullish about Rezdiffra's prospects, or impatient for the recently ...